IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. IQVIA Holdings Inc. has a strategic alliance with MuleSoft, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
SymbolNYSE:IQV
CUSIPN/A
Phone919-998-2000
Debt
Debt-to-Equity Ratio1.40
Current Ratio1.13
Quick Ratio1.13
Price-To-Earnings
Trailing P/E Ratio29.26
Forward P/E Ratio24.87
P/E Growth1.82
Sales & Book Value
Annual Sales$9.74 billion
Price / Sales2.65
Cash Flow$9.8063 per share
Price / Cash13.01
Book Value$40.19 per share
Price / Book3.17
Profitability
EPS (Most Recent Fiscal Year)$4.36
Net Income$1.31 billion
Net Margins12.68%
Return on Equity13.51%
Return on Assets4.74%
Miscellaneous
Employees55,000
Outstanding Shares202,590,000
Market Cap$25.76 billion
Iqvia (NYSE:IQV) Frequently Asked Questions
What is Iqvia's stock symbol?
Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."
How were Iqvia's earnings last quarter?
Iqvia Holdings Inc (NYSE:IQV) released its earnings results on Tuesday, July, 24th. The medical research company reported $1.29 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.14 by $0.15. The medical research company had revenue of $2.57 billion for the quarter, compared to analysts' expectations of $2.50 billion. Iqvia had a return on equity of 13.51% and a net margin of 12.68%. The business's revenue for the quarter was up 9.0% on a year-over-year basis. View Iqvia's Earnings History.
When is Iqvia's next earnings date?
What guidance has Iqvia issued on next quarter's earnings?
Iqvia updated its FY18 earnings guidance on Tuesday, July, 24th. The company provided EPS guidance of $5.35-5.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.40. The company issued revenue guidance of $10.25-10.4 billion, compared to the consensus revenue estimate of $10.24 billion.Iqvia also updated its Q3 guidance to $1.35-1.42 EPS.
What price target have analysts set for IQV?
18 Wall Street analysts have issued twelve-month price objectives for Iqvia's stock. Their predictions range from $97.00 to $150.00. On average, they anticipate Iqvia's share price to reach $127.6667 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price. View Analyst Price Targets for Iqvia.
What is the consensus analysts' recommendation for Iqvia?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 4 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.
Who are some of Iqvia's key competitors?
Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and VIRALYTICS Ltd/S (VRACY).
Who are Iqvia's key executives?
Iqvia's management team includes the folowing people:
- Mr. Ari Bousbib, Chairman, CEO & Pres (Age 57)
- Mr. Michael R. McDonnell, Exec. VP & CFO (Age 54)
- Mr. W. Richard Staub III, Pres of R&D Solutions (Age 55)
- Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 57)
- Mr. James H. Erlinger III, Consultant (Age 60)
Who are Iqvia's major shareholders?
Iqvia's stock is owned by many different of institutional and retail investors. Top institutional investors include TPG Group Holdings SBS Advisors Inc. (7.97%), BlackRock Inc. (5.02%), Longview Partners Guernsey LTD (4.78%), Canada Pension Plan Investment Board (3.68%), Janus Henderson Group PLC (1.46%) and Northern Trust Corp (0.93%). Company insiders that own Iqvia stock include Ari Bousbib, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Robert Parks and Ronald A Rittenmeyer. View Institutional Ownership Trends for Iqvia.
Which institutional investors are selling Iqvia stock?
IQV stock was sold by a variety of institutional investors in the last quarter, including TPG Group Holdings SBS Advisors Inc., Canada Pension Plan Investment Board, Renaissance Technologies LLC, Jennison Associates LLC, Janus Henderson Group PLC, Mackay Shields LLC, Bank of America Corp DE and Longview Partners Guernsey LTD. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Cpp Investment Board Private H, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Robert Parks and Ronald A Rittenmeyer. View Insider Buying and Selling for Iqvia.
Which institutional investors are buying Iqvia stock?
IQV stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Laurion Capital Management LP, BlackRock Inc., Retirement Systems of Alabama, Chilton Investment Co. LLC, Unigestion Holding SA, FMR LLC and Northern Trust Corp. View Insider Buying and Selling for Iqvia.
How do I buy shares of Iqvia?
Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iqvia's stock price today?
One share of IQV stock can currently be purchased for approximately $127.58.
How big of a company is Iqvia?
Iqvia has a market capitalization of $25.76 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. Iqvia employs 55,000 workers across the globe.
What is Iqvia's official website?
How can I contact Iqvia?
Iqvia's mailing address is 83 WOOSTER HEIGHTS ROAD, DANBURY CT, 06810. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]
MarketBeat Community Rating for Iqvia (NYSE IQV)
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
